Heart disease is still the leading cause of death in the United States, claiming nearly 950,000 lives a year, and nearly half of U.S. adults have high blood pressure, the most modifiable risk factor (American Heart Association, 2025). Those facts have held for a generation. What changed inside the last fiscal year is who gets to explain them.
First, the drugs. GLP-1 and GIP medications began posting cardiovascular outcomes that move prevention from the clinic to the pharmacy counter. An oral semaglutide trial in more than 9,600 high-risk adults showed a notably lower risk of heart attack, stroke, or cardiovascular death (New England Journal of Medicine, 2025). The Association funds this work through its Precision Medicine Platform. The consumer story is written by the companies that sell the drugs.
Second, the funding base. In February 2025 the Association issued a Presidential Advisory defending the National Institutes of Health against funding cuts (Circulation, 2025). Its role as the largest non-governmental funder of cardiovascular research becomes load-bearing when the federal base wavers.
Third, the nutrition fight. New federal dietary guidance in January 2026 stepped back from decades of saturated-fat caution, and the Association publicly disputed it (NPR, January 2026). A century of trusted science meets a year in which the public conversation about the heart is narrated by others.